Clinical Laboratories

The U.S. clinical laboratory market including both hospitals and separate lab facilities is expected to see a compound annual growth rate of eight percent annually, between 2010 and 2018 (source: Lab Industry Analysis 2010). In 2009, this market was valued at $58 billion, according to Washington G-2 reports. Meanwhile, laboratories in the private, public, non-profit and academic sectors are expected to cumulatively generate $108 billion in sales between 2010 and 2018, an increase of 86 percent.

Demands for this increase in the diagnostic testing market include favorable reimbursement policies for clinical labs, growing awareness about early disease detection and an aging population. While globally the U.S. is the dominant diagnostic market, other significant markets include the Europen Union and Japan.

Despite demands for growth in this market sector, clinical laboratories still have little choice but to wait days for positive identification of viable pathogenic bacteria via conventional Petri methods. The typical waiting period is 18-48 hours for Methicillin-resistant Staphylococcus aureus (MRSA) and Staph, and Petri cultures take 72 hours to return results for Group B Streptococcus. These are just a few examples in a long list of lethal, pathogenic agents.

PCR protocol seems to solve this problem of slow microorganism growth, but culturing is still required as a first step. In addition, the tests are expensive and require specialized equipment and training. Most importantly, PCR protocol does not provide live cell detection. For more definitive results, clinical laboratories prefer to culture samples in Petri dishes and run their operations on a “microbe’s timetable.”

In clinical settings, long wait times force physicians to treat empirically with broad-spectrum antibiotics. In the 24-48 hours that it takes to return results from a conventional Petri culture test for Methicillin-resistant Staphylococcus aureus (MRSA) a patient is likely to be administered antibiotics until test results indicate a more specific protocol. Broad-spectrum antibiotics are used to treat several types of illness and their over-use has contributed to growing antibiotic resistance.

In contrast, NanoLogix technology provides rapid detection of live-cell MRSA bacteria in as little as six hours. With significantly faster results like these, physicians have the opportunity to administer the specific antibiotic necessary for targeted treatment. Thus, rapid detection and treatment reduces the potential for further development of antibiotic-resistance.

Faster live-cell test results from NanoLogix give physicians and public health officials the ability to make more confident, informed decisions regarding patient treatment and public safety. This improved decision-making results in more beneficial patient outcomes and reduces the overuse of antibiotics. In addition, the simplicity of the NanoLogix technology means medical settings in rural or under-treated areas can also benefit from these rapid diagnostics. Thus, NanoLogix offers solutions to laboratories looking for a competitive edge, as well as to expand their reach into areas of need.